135 related articles for article (PubMed ID: 22505562)
1. Blood presence of circulating oncofetal fibronectin mRNA, by RT-PCR, does not represent a useful specific marker for the management and follow-up of thyroid cancer patients.
Vendittelli F; Raffaelli M; Fadda G; Carelli-Alinovi C; Paolillo C; Bellantone R; Zuppi C; Capoluongo E
Clin Chem Lab Med; 2012 Jan; 50(4):715-20. PubMed ID: 22505562
[TBL] [Abstract][Full Text] [Related]
2. Oncofoetal fibronectin--a tumour-specific marker in detecting minimal residual disease in differentiated thyroid carcinoma.
Hesse E; Musholt PB; Potter E; Petrich T; Wehmeier M; von Wasielewski R; Lichtinghagen R; Musholt TJ
Br J Cancer; 2005 Sep; 93(5):565-70. PubMed ID: 16091757
[TBL] [Abstract][Full Text] [Related]
3. Galectin-3 and oncofetal-fibronectin expression in thyroid neoplasia as assessed by reverse transcription-polymerase chain reaction and immunochemistry in cytologic and pathologic specimens.
Giannini R; Faviana P; Cavinato T; Elisei R; Pacini F; Berti P; Fontanini G; Ugolini C; Camacci T; De Ieso K; Miccoli P; Pinchera A; Basolo F
Thyroid; 2003 Aug; 13(8):765-70. PubMed ID: 14558920
[TBL] [Abstract][Full Text] [Related]
4. Serum oncofetal fibronectin (onfFN) mRNA in differentiated thyroid carcinoma (DTC): large overlap between disease-free and metastatic patients.
Sritara C; Charoenphun P; Ponglikitmongkol M; Musikarat S; Utamakul C; Chokesuwattanasakul P; Thakkinstian A
Asian Pac J Cancer Prev; 2012; 13(8):4203-8. PubMed ID: 23098431
[TBL] [Abstract][Full Text] [Related]
5. Oncofetal fibronectin mRNA is highly abundant in the blood of patients with papillary thyroid carcinoma and correlates with high-serum thyroid-stimulating hormone levels.
Wehmeier M; Petrich T; Brand K; Lichtinghagen R; Hesse E
Thyroid; 2010 Jun; 20(6):607-13. PubMed ID: 20470202
[TBL] [Abstract][Full Text] [Related]
6. Preoperative diagnosis of thyroid papillary and anaplastic carcinomas by real-time quantitative reverse transcription-polymerase chain reaction of oncofetal fibronectin messenger RNA.
Takano T; Miyauchi A; Yokozawa T; Matsuzuka F; Maeda I; Kuma K; Amino N
Cancer Res; 1999 Sep; 59(18):4542-5. PubMed ID: 10493503
[TBL] [Abstract][Full Text] [Related]
7. Blood thyroglobulin and TSH receptor mRNA detection by RT-PCR in the follow-up of differentiated thyroid cancer patients.
Torosian L; Manrique G; Alvarez B; Lago G; Roca R; Belzarena C
Rev Esp Med Nucl; 2010; 29(3):109-13. PubMed ID: 20399540
[TBL] [Abstract][Full Text] [Related]
8. Expression of oncofetal fibronectin mRNA in thyroid anaplastic carcinoma.
Takano T; Ito Y; Matsuzuka F; Miya A; Kobayashi K; Yoshida H; Miyauchi A
Jpn J Clin Oncol; 2007 Sep; 37(9):647-51. PubMed ID: 17704536
[TBL] [Abstract][Full Text] [Related]
9. Expression of oncofetal fibronectin messenger ribonucleic acid in fibroblasts in the thyroid: a possible cause of false positive results in molecular-based diagnosis of thyroid carcinomas.
Takano T; Miyauchi A; Matsuzuka F; Kuma K; Amino N
J Clin Endocrinol Metab; 2000 Feb; 85(2):765-8. PubMed ID: 10690888
[TBL] [Abstract][Full Text] [Related]
10. Molecular detection of thyroglobulin mRNA transcripts in peripheral blood of patients with thyroid disease by RT-PCR.
Bojunga J; Röddiger S; Stanisch M; Kusterer K; Kurek R; Renneberg H; Adams S; Lindhorst E; Usadel KH; Schumm-Draeger PM
Br J Cancer; 2000 May; 82(10):1650-5. PubMed ID: 10817499
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of quantitative measurement of thyroglobulin mRNA in the follow-up of differentiated thyroid cancer.
Denizot A; Delfino C; Dutour-Meyer A; Fina F; Ouafik L
Thyroid; 2003 Sep; 13(9):867-72. PubMed ID: 14588101
[TBL] [Abstract][Full Text] [Related]
12. Thyroglobulin mRNA quantification in the peripheral blood is not a reliable marker for the follow-up of patients with differentiated thyroid cancer.
Eszlinger M; Neumann S; Otto L; Paschke R
Eur J Endocrinol; 2002 Nov; 147(5):575-82. PubMed ID: 12444888
[TBL] [Abstract][Full Text] [Related]
13. Real time RT-PCR analysis of thyroglobulin mRNA in peripheral blood in patients with congenital athyreosis and with differentiated thyroid carcinoma after stimulation with recombinant human thyrotropin.
Kaufmann S; Schmutzler C; Schomburg L; Körber C; Luster M; Rendl J; Reiners C; Köhrle J
Endocr Regul; 2004 Jun; 38(2):41-9. PubMed ID: 15497927
[TBL] [Abstract][Full Text] [Related]
14. Real-time quantitative PCR measurement of thyroglobulin mRNA in peripheral blood of thyroid cancer patients and healthy subjects.
Li D; Butt A; Clarke S; Swaminathana R
Ann N Y Acad Sci; 2004 Jun; 1022():147-51. PubMed ID: 15251954
[TBL] [Abstract][Full Text] [Related]
15. [Aspiration biopsy-RT-PCR(ABRP): lesson from its success].
Takano T; Amino N
Rinsho Byori; 2001 Dec; 49(12):1248-54. PubMed ID: 11797396
[TBL] [Abstract][Full Text] [Related]
16. Development of a sensitive and specific quantitative reverse transcription-polymerase chain reaction assay for blood thyroglobulin messenger ribonucleic acid in the follow-up of patients with differentiated thyroid carcinoma.
Boldarine VT; Maciel RM; Guimarães GS; Nakabashi CC; Camacho CP; Andreoni DM; Mamone Mda C; Ikejiri ES; Kasamatsu TS; Crispim F; Hojaij FC; Hidal JT; Biscolla RP
J Clin Endocrinol Metab; 2010 Apr; 95(4):1726-33. PubMed ID: 20173019
[TBL] [Abstract][Full Text] [Related]
17. Low specificity of blood thyroglobulin messenger ribonucleic acid assay prevents its use in the follow-up of differentiated thyroid cancer patients.
Elisei R; Vivaldi A; Agate L; Molinaro E; Nencetti C; Grasso L; Pinchera A; Pacini F
J Clin Endocrinol Metab; 2004 Jan; 89(1):33-9. PubMed ID: 14715824
[TBL] [Abstract][Full Text] [Related]
18. Measurement of thyroglobulin mRNA in peripheral blood as an adjunctive test for monitoring thyroid cancer.
Grammatopoulos D; Elliott Y; Smith SC; Brown I; Grieve RJ; Hillhouse EW; Levine MA; Ringel MD
Mol Pathol; 2003 Jun; 56(3):162-6. PubMed ID: 12782763
[TBL] [Abstract][Full Text] [Related]
19. Thyrotropin receptor/thyroglobulin messenger ribonucleic acid in peripheral blood and fine-needle aspiration cytology: diagnostic synergy for detecting thyroid cancer.
Wagner K; Arciaga R; Siperstein A; Milas M; Warshawsky I; Sethu S; Reddy K; Gupta MK
J Clin Endocrinol Metab; 2005 Apr; 90(4):1921-4. PubMed ID: 15687333
[TBL] [Abstract][Full Text] [Related]
20. Molecular diagnosis of residual and recurrent thyroid cancer by amplification of thyroglobulin messenger ribonucleic acid in peripheral blood.
Ringel MD; Ladenson PW; Levine MA
J Clin Endocrinol Metab; 1998 Dec; 83(12):4435-42. PubMed ID: 9851791
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
